KRAS G12D MUTATION
Clinical trials for KRAS G12D MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D MUTATION trials appear
Sign up with your email to follow new studies for KRAS G12D MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets 'Undruggable' cancer mutation in first human trial
Disease control Recruiting nowThis is the first study to test a new drug called ARV-806 in people with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to find a safe dose and see how the body processes the drug, while also looking for early signs that it can shrink tumors. Th…
Matched conditions: KRAS G12D MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New pill targets 'Undruggable' cancer mutation in first human tests
Disease control Recruiting nowThis is the first study in people to test a new oral medication called RNK08954. It aims to find a safe and effective dose for adults with advanced solid tumors that have a specific genetic change called a KRAS G12D mutation. The study will also see if the drug can help control t…
Matched conditions: KRAS G12D MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC